These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2804664)

  • 1. The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study.
    Gerhardt GA; Friedemann M; Brodie MS; Vickroy TW; Gratton AP; Hoffer BJ; Rose GM
    Brain Res; 1989 Oct; 499(1):157-63. PubMed ID: 2804664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro.
    Voigt M; Wang RY; Westfall TC
    J Pharmacol Exp Ther; 1986 Apr; 237(1):147-53. PubMed ID: 3958963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic administration of CCK-8S, but not CCK-4, enhances dopamine turnover in the posterior nucleus accumbens: a microdialysis study in freely moving rats.
    Kariya K; Tanaka J; Nomura M
    Brain Res; 1994 Sep; 657(1-2):1-6. PubMed ID: 7820607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats.
    Hamilton ME; Freeman AS
    Brain Res; 1995 Aug; 688(1-2):134-42. PubMed ID: 8542299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin facilitates methamphetamine-induced dopamine overflow in rat striatum and fetal ventral mesencephalic grafts.
    Wang Y; Perng SL; Lin JC; Tsao WL
    Exp Neurol; 1994 Dec; 130(2):279-87. PubMed ID: 7867757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.
    Voigt MM; Wang RY
    Brain Res; 1984 Mar; 296(1):189-93. PubMed ID: 6324955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.
    Kombian SB; Ananthalakshmi KV; Parvathy SS; Matowe WC
    J Physiol; 2004 Feb; 555(Pt 1):71-84. PubMed ID: 14673185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry.
    Reum T; Fink H; Marsden CA; Morgenstern R
    Neuropeptides; 1998 Apr; 32(2):161-6. PubMed ID: 9639255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological effects of cholecystokinin octapeptide on identified rat nigrostriatal dopaminergic neurons.
    Freeman AS; Chiodo LA
    Brain Res; 1988 Jan; 439(1-2):266-74. PubMed ID: 3359189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.
    Marshall FH; Barnes S; Pinnock RD; Hughes J
    Br J Pharmacol; 1990 Apr; 99(4):845-8. PubMed ID: 2361176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry.
    Reum T; Schäfer U; Marsden CA; Fink H; Morgenstern R
    Neuropeptides; 1997 Feb; 31(1):82-8. PubMed ID: 9574843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cholecystokinin-octapeptide on dopamine release from slices of cat caudate nucleus.
    Markstein R; Hökfelt T
    J Neurosci; 1984 Feb; 4(2):570-5. PubMed ID: 6321698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration.
    Hamilton ME; Redondo JL; Freeman AS
    Synapse; 2000 Dec; 38(3):238-42. PubMed ID: 11020226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat.
    Blaha CD; Phillips AG; Lane RF
    Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.